MECP2
Recent articles
Parasite-based tool delivers MECP2 and other proteins to neurons
A method that uses a common brain parasite could help replenish the proteins deficient in Rett syndrome and other conditions.
Parasite-based tool delivers MECP2 and other proteins to neurons
A method that uses a common brain parasite could help replenish the proteins deficient in Rett syndrome and other conditions.
Autism-linked genes shape touch processing through different mechanisms, at different times
Whereas some mice display hypersensitivity to touch only as adults, others respond that way from birth.
Autism-linked genes shape touch processing through different mechanisms, at different times
Whereas some mice display hypersensitivity to touch only as adults, others respond that way from birth.
On the periphery: Thinking ‘outside the brain’ offers new ideas about autism
Neuronal alterations outside the brain may help to explain a host of the condition’s characteristic traits, including sensory changes, gut problems and motor differences.
On the periphery: Thinking ‘outside the brain’ offers new ideas about autism
Neuronal alterations outside the brain may help to explain a host of the condition’s characteristic traits, including sensory changes, gut problems and motor differences.
FDA approval of trofinetide may spur further drug development for Rett
The drug, welcomed by patients, might be just the first of many.
FDA approval of trofinetide may spur further drug development for Rett
The drug, welcomed by patients, might be just the first of many.
Debut drug for Rett syndrome at edge of approval
The U.S. Food and Drug Administration plans to make an approval decision on the first-ever drug for girls and women with Rett syndrome by 12 March.
Debut drug for Rett syndrome at edge of approval
The U.S. Food and Drug Administration plans to make an approval decision on the first-ever drug for girls and women with Rett syndrome by 12 March.
Going on Trial: Orphan drugs; CBD; bumetanide
This month’s newsletter takes a close look at the orphan drug program in the United States, several cannabis-based therapies and a secondary analysis of bumetanide, among other new developments in autism-related drug trials.
Going on Trial: Orphan drugs; CBD; bumetanide
This month’s newsletter takes a close look at the orphan drug program in the United States, several cannabis-based therapies and a secondary analysis of bumetanide, among other new developments in autism-related drug trials.
Epigenome edits unmute MECP2 in Rett-like neurons
The approach removes methyl tags from the gene and shields it from other silencing factors without changing the gene itself, raising hopes for a new treatment.
Epigenome edits unmute MECP2 in Rett-like neurons
The approach removes methyl tags from the gene and shields it from other silencing factors without changing the gene itself, raising hopes for a new treatment.
RNA rewrite improves breathing, survival in Rett mice
The technique involves editing the cellular instructions to make MECP2 protein and partially restores its levels in the brainstem.
RNA rewrite improves breathing, survival in Rett mice
The technique involves editing the cellular instructions to make MECP2 protein and partially restores its levels in the brainstem.
Portrait of a research field: astrocytes in autism
Long cast in supporting roles in the brain, astrocytes are now emerging as primary players in certain characteristics of autism and related conditions.
Portrait of a research field: astrocytes in autism
Long cast in supporting roles in the brain, astrocytes are now emerging as primary players in certain characteristics of autism and related conditions.
Faulty inhibition foils long-term memory in Rett mice
The animals recall fear more readily if a set of inhibitory neurons in the hippocampus is switched on.
Faulty inhibition foils long-term memory in Rett mice
The animals recall fear more readily if a set of inhibitory neurons in the hippocampus is switched on.
Explore more from The Transmitter
To keep or not to keep: Neurophysiology’s data dilemma
An exponential growth in data size presents neuroscientists with a significant challenge: Should we be keeping all raw data or focusing on processed datasets? I asked experimentalists and theorists for their thoughts.
To keep or not to keep: Neurophysiology’s data dilemma
An exponential growth in data size presents neuroscientists with a significant challenge: Should we be keeping all raw data or focusing on processed datasets? I asked experimentalists and theorists for their thoughts.
Neuroscientists reeling from past cuts advocate for more BRAIN Initiative funding
The director of the U.S. National Institutes of Health calls BRAIN a “high priority” but acknowledges that difficult decisions lie ahead if federal budgets remain flat.
Neuroscientists reeling from past cuts advocate for more BRAIN Initiative funding
The director of the U.S. National Institutes of Health calls BRAIN a “high priority” but acknowledges that difficult decisions lie ahead if federal budgets remain flat.
‘Huge influx’ of neuroscientists migrates to Bluesky
Daily neuroscience-related posts on the social-media platform this week have increased more than 400 percent, on average, compared with October.
‘Huge influx’ of neuroscientists migrates to Bluesky
Daily neuroscience-related posts on the social-media platform this week have increased more than 400 percent, on average, compared with October.